Effect of Heatwave Over Glycemic Control in Patients With T1D

Sponsor
Castilla-La Mancha Health Service (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05646017
Collaborator
(none)
2,701
9
1.5
300.1
194.4

Study Details

Study Description

Brief Summary

Observational study about effect of the greatest Spanish heatwave over glycemic contro in adult patients with type 1 Diabetes mellitus.

Condition or Disease Intervention/Treatment Phase
  • Device: Intermittenly scanned continuous glucose monitoring

Detailed Description

Cross-sectional retrospective analysis of all patients with T1D in Castilla-La Mancha (south-central Spanish region) using intermittently scanned continuous glucose monitoring (isCGM). Glycometric data obtained through deidentified downloads from isCGM´s webpage. Primary outcome was time in range (TIR) 3.0-10 mmol/L (70-180 mg/d) change after the heatwave. Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon signed-rank test were used for the analysis of differences. Comparisons between proportions were analyzed using a chi-squared test. A P value < 0.05 was considered statistically significant. The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic Committee.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2701 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Effect of the Greatest Spanish Heatwave Over Glycemic Control in Adult Patients With Type 1 Diabetes
Anticipated Study Start Date :
Dec 15, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Type 1 diabetes patients

Type 1 diabetes patients using intermittently continuous glucose monitoring during the Spanish greatest heatwave in Castilla-La Mancha (Spain).

Device: Intermittenly scanned continuous glucose monitoring
Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
Other Names:
  • FreeStyle Libre
  • isCGM
  • FSL
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Time in range [14 days]

      Change in Time in range (TIR) 3.0-10 mmol/L (70-180 mg/d) of interstitial glucose from the heatwave period to 14 days after its end

    Secondary Outcome Measures

    1. Change in Adherence to Flash 1 [14 days]

      Change in Time of use of intermittently scanned continuous glucose monitoring (% possible time of use) from the heatwave period to 14 days after its end

    2. Change in Adherence to Flash 2 [14 days]

      Change in Number of intermittently scanned continuous glucose monitoring daily scanning (number of scans/day) from the heatwave period to 14 days after its end

    3. Change in Time below range 1 (TBR1) [14 days]

      Change in Time bellow range <3.9 mmol/L (<70 mg/dL) of the interstitial glucose from the heatwave period to 14 days after its endfrom the heatwave period to 14 days after its end

    4. Change in Time below range 2 (TBR2) [14 days]

      Change in Time bellow range <3 mmol/L (<54 mg/dL) of the interstitial glucose from the heatwave period to 14 days after its end

    5. Change in Time above range 1 (TAR1) [14 days]

      Change in Time above range >10 mmol/L(>180 mg/dL) of the interstitial glucose from the heatwave period to 14 days after its end

    6. Change in Time above range 2 (TAR2) [14 days]

      Change in Time above range >13.9 mmol/L (>250 mg/dL) of the interstitial glucose from the heatwave period to 14 days after its end

    7. Change in Coefficient of variation percentage (CV) [14 days]

      Change in Coefficient of variation percentage of interstitial glucose from the heatwave period to 14 days after its end

    8. Change in Glucose management index [14 days]

      Change in Glucose management index of interstitial glucose from the heatwave period to 14 days after its end

    9. Change in Time in hypoglycemia [14 days]

      Change in Daily time in hypoglycemia (<3.9 mmol/L, <70 mg/dL) of interstitical glucose from the heatwave period to 14 days after its end

    10. Change in Hypoglycemia frequency [14 days]

      Change in Number of daily hypoglycemic events (<3.9 mmol/L, <70 mg/dL) of interstitical glucose from the heatwave period to 14 days after its end

    Other Outcome Measures

    1. Change in Percentage of patients attaining the the International Consensus on Time in Range (ICTR) goals [14 days]

      Change in Percentage of patients (from total) attaining TIR>70%, TBR1<4%, TBR2<1%, TAR1<25%, TAR2<5% and CV <36% from the heatwave period to 14 days after its end

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Type 1 diabetes

    • Older than 18 years old

    • Using intermittently scanned continuous glucose monitoring (isCGM)

    • Paired active isCGM data from the heatwave period and two consecutive weeks

    Exclusion Criteria:
    • Younger than 18 years old

    • Not using intermittently scanned continuous glucose monitoring

    • Not having active paired isCGM data from the analyzed periods

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 La Mancha-Centro Hospital Alcázar De San Juan Ciudad Real Spain 13600
    2 Santa Barbara Hospital Puertollano Ciudad Real Spain 13500
    3 Valdepeñas General Hospital Valdepeñas Ciudad Real Spain 13300
    4 Virgen del Prado Hospital Talavera De La Reina Toledo Spain 45600
    5 Albacete University Hospital Albacete Spain 02006
    6 Ciudad Real General University Hospital Ciudad Real Spain 13005
    7 Virgen de la Luz University Hospital Cuenca Spain 16002
    8 Guadalajara University Hospital Guadalajara Spain 19002
    9 Toledo University Hospital Toledo Spain 45007

    Sponsors and Collaborators

    • Castilla-La Mancha Health Service

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Castilla-La Mancha Health Service
    ClinicalTrials.gov Identifier:
    NCT05646017
    Other Study ID Numbers:
    • C-566
    First Posted:
    Dec 12, 2022
    Last Update Posted:
    Dec 12, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Castilla-La Mancha Health Service
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 12, 2022